Table 1.
Ref.
|
Study design
|
Aim
|
Number of patients
|
Results and conclusion
|
Mohamad et al[5], 2016 | Retrospective | To characterize patients with NAFLD and HCC comparing cirrhotic vs non-cirrhotic patients | All patients with NAFLD and HCC between 2003-2012 (n = 83) | 36 (43.4%) NAFLD HCC non-cirrhotic vs 47 (56.6%) NAFLD HCC cirrhotic patients. HCC patients without cirrhosis are more likely to present at an older age with larger tumor and higher rates of tumor recurrence |
Piscaglia et al[6], 2016 | Multicenter observational prospective | To assess the clinical features of patients with NAFLD-related HCC and to compare to those with HCV related HCC | N = 756 (145 NAFLD vs 611 HCV) | Cirrhosis was present in about 50% of NAFLD-HCC patients, in contrast to the near totality of HCV-HCC. Survival was significantly shorter in patients with NAFLD-HCC than in those with HCV-HCC (25.5 mo vs 33.7 mo) |
Stine et al[9], 2018 | Systematic review with meta-analysis | To compare the prevalence of NAFLD-related HCC to other chronic liver diseases | 19 studies (n = 168571) | The prevalence of NAFLD-related HCC in patients with NASH without cirrhosis is approximately 38% compared with 14% for other liver diseases |
Tobari et al[24], 2020 | Prospective | To evaluate the characteristics of HCC in non-cirrhotic NAFLD | 48 non-cirrhotic HCC vs 71 cirrhotic HCC patients | In patients with non-cirrhotic NAFLD, important risk factors for HCC were male gender, alcohol consumption, and the FIB-4 index. HCC recurrence and survival were only influenced by the tumor stage |
Kanwal et al[27], 2018 | Retrospective | To estimate the risk of incident HCC among patients with NAFLD | 296707 NAFLD vs 296707 matched controls | NAFLD individuals with cirrhosis had the highest annual incidence of HCC. 20% of NAFLD patients with HCC had no evidence of cirrhosis. The absolute risk of HCC in patients without cirrhosis is too low to recommend HCC surveillance |
Orci et al[28], 2022 | Systematic review with meta-analysis | Evaluate the pooled HCC incidence in patients with NAFLD at distinct severity stages | 18 studies (470404 individuals) | Evidence documenting the risk in patients with NASH or simple steatosis is limited, but the incidence of HCC in these populations may lie below thresholds used to recommend a screening (0.03 per 100 person-years) |
Donati et al[34], 2017 | Sectional | To evaluate whether the MBOAT7 rs641738 risk T allele predisposes to HCC in NAFLD patients stratified by the presence of severe fibrosis | 765 Italian NAFLD patients | The MBOAT7 rs641738 T allele is associated with reduced MBOAT7 expression and may predispose to HCC in patients without cirrhosis |
Demirtaş et al[71], 2021 | Retrospective | To investigate the characteristics and survival course of non-cirrhotic individuals with HCC | N = 384 HCC; 43 (11.2%) without cirrhosis; 10 (23%) with NAFLD | HCC in non-cirrhotic liver is diagnosed at more advanced stage and with larger tumor size. The overall survival is shorter in HCC without cirrhosis, due to late recognition |
NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; MBOAT7: Membrane-bound o-acyltransferase domain-containing 7.